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P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) are expressed in the
intestine and are associated with drug absorption and metabolism. Pregnane X receptor
(PXR) is the key molecule that regulates the expression of P-gp and CYP3A4. Given that
PXR activity is regulated by a variety of compounds, it is possible that unknown PXR
activators exist among known medicines. Kampo is a Japanese traditional medicine
composed of various natural compounds. In particular, immature orange [Aurantii fructus
immaturus (IO)] and citrus unshiu peel [Citri unshiu pericarpium (CP)] are common
ingredients of kampo. A previous study reported that kampo containing IO or CP
decreased the blood concentration of concomitant drugs via upregulation of CYP3A4
although the mechanism was unclear. Some flavonoids are indicated to alter P-gp
and CYP3A4 activity via changes in PXR activity. Because IO and CP include various
flavonoids, we speculated that the activity of P-gp and CYP3A4 in the intestine may
be altered via changes in PXR activity when IO or CP is administered. We tested
this hypothesis by using LS180 intestinal epithelial cells. The ethanol extract of IO
contained narirutin and naringin, and that of CP contained narirutin and hesperidin.
Ethanol extracts of IO and CP induced P-gp, CYP3A4, and PXR expression. The
increase of P-gp and CYP3A4 expression by the IO and CP ethanol extracts was
inhibited by ketoconazole, an inhibitor of PXR activation. The ethanol extract of IO
and CP decreased the intracellular concentration of digoxin, a P-gp substrate, and this
decrease was inhibited by cyclosporine A, a P-gp inhibitor. In contrast, CP, but not IO,
Frontiers in Pharmacology | www.frontiersin.org 1 February 2017 | Volume 8 | Article 84
fphar-08-00084 February 17, 2017 Time: 18:4 # 2
Okada et al. Kampo Ingredients Alter Drug Bioavailability
stimulated the metabolism of testosterone, a CYP3A4 substrate, and this was inhibited
by a CYP3A4 inhibitor. These findings indicate that the ethanol extract of IO and CP
increased P-gp and CYP3A4 expression via induction of PXR protein. Moreover, this
induction decreased the intracellular substrate concentration.
Keywords: Kampo, immature orange, citrus unshiu peel, P-glycoprotein, cytochrome P450 3A4, pregnane X
receptor, Drug–Drug Interaction
INTRODUCTION
The intestine functions in the first step of drug absorption.
P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4)
are expressed in intestinal epithelial cells and play important
roles in this process (Gupta et al., 2008). P-gp is a member
of the ATP-binding cassette superfamily of transmembrane
proteins and plays a role in the extrusion of a wide variety of
substrates (Ambudkar et al., 1999) by intestinal epithelial cells
to decrease intracellular substrate concentrations (Harmsen
et al., 2010; Sridhar et al., 2014). CYP3A4 is involved in the
metabolism of various drugs, and its activation decreases
intracellular substrate concentrations (Kolars et al., 1992;
Paine et al., 1996; Ruschitzka et al., 2000); specifically,
changes in CYP3A4 activity in intestinal epithelial cells
affect the bioavailability of drugs. Inhibition of CYP3A4
activity in intestinal epithelial cells increased substrate
concentrations in blood (Ohnishi et al., 2000). Therefore,
monitoring of changes in P-gp and CYP3A4 activity is
important for estimating drug absorption and metabolism
in the intestine.
Various compounds modulate P-gp and CYP3A4 levels
in the intestine. 1α, 25-Dihydroxyvitamin D3 (VD3) induces
their expression via vitamin D receptor (VDR; Schmiedlin-
Ren et al., 2001; Thummel et al., 2001), whereas some drugs
increase the activity of the nuclear pregnane X receptor
(PXR), which upregulates the expression of P-gp and CYP3A4
(Ma et al., 2005). Intestinal PXR activation induces P-gp
and CYP3A4 expression and reduces drug bioavailability by
increasing drug eﬄux and drug metabolism in the intestine
(Holmstock et al., 2013; Kawauchi et al., 2014). Given that
PXR activity is regulated by a variety of compounds, it is
possible that there are unknown drug interactions associated
with PXR-induced P-gp or CYP3A4 in intestinal epithelial
cells.
Kampo is a traditional Japanese medicine that has been
approved by the Ministry of Health, Labor and Welfare
of Japan. Kampo medicines are used in combination with
western medications or alone as a complementary or alternative
therapy. They are a blend of herbal components, which makes
it difficult to predict their interaction with concomitantly
consumed drugs. Immature orange [Aurantii fructus immaturus
(IO)] and citrus unshiu peel [Citri unshiu pericarpium (CP)]
are common ingredients of kampo that are reported to have
anti-hypercholesterolemic or orexigenic effects (Yoshie et al.,
2004; Hayakawa et al., 2014). However, a previous study
reported that kampo containing IO or CP decreased the
blood concentration of concomitantly administered CYP3A4
substrates via upregulation of CYP3A4 although the mechanism
was unclear (Kinoshita et al., 2011). IO and CP include
some flavonoids that have pharmacological effects (Tokunaga
et al., 2016). Some flavonoids have been indicated to alter
P-gp and CYP3A4 activity via changes in PXR activity
(Hiura et al., 2014). Therefore, we speculated that the
activity of P-gp and CYP3A4 in the intestine may be
altered via changes in PXR activity when IO or CP is
administered.
To test this hypothesis, in the present study, we analyzed
the effects of IO and CP on P-gp and CYP3A4 expression in
LS180 intestinal epithelial cells. Our findings provide insight into
potential interactions between kampo containing IO or CP and
other drugs via the upregulation of P-gp and CYP3A4 in the
intestine as well as a guideline for improving the safety of kampo
treatment.
MATERIALS AND METHODS
Materials
IO (#24014051) and CP (#24014541) were purchased from
Tsumura (Tokyo, Japan). LS180 cells were purchased from the
American Type Culture Collection (Manassas, VA, USA). VD3
and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Digoxin was purchased from Tokyo
Kagaku (Tokyo, Japan). Cyclosporine A, ketoconazole,
rifampicin, and testosterone were purchased from Wako
Pure Chemical Industries (Osaka, Japan). Dulbecco’s Modified
Eagle Medium (DMEM)+GlutaMAX-1, non-essential amino
acids, penicillin/streptomycin, and fetal bovine serum (FBS)
were purchased from Life Technologies (Tokyo, Japan),
Nacalai Tesque (Tokyo, Japan), DS Pharma Biomedical
(Osaka, Japan), and Biowest (Nuaillé, France), respectively.
Mouse anti-CYP3A4 (ab3572) and rabbit anti-P-gp (ab3366)
antibodies were purchased from Abcam (Cambridge, UK).
Rabbit anti-β-actin antibody (#4967) was purchased from
Cell Signaling Technology (Beverly, MA, USA). Mouse anti-
PXR antibody (SC-48403) was purchased from Santa Cruz
Biotechnology (Dallas, TX, USA). Horseradish peroxidase-
conjugated sheep anti-mouse IgG and anti-rabbit IgG
and enhanced chemiluminescence (ECL) western blotting
detection reagent were purchased from GE Healthcare
Japan (Tokyo, Japan). The Multi-Drug Resistance Assay
and P450-Glo Assay kits were purchased from Cayman
Chemical (Ann Arbor, MI, USA) and Promega (Madison,
WI, USA), respectively. Architect digoxin and testosterone
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assay kits were purchased from Abbot Japan (Tokyo,
Japan).
Ethanol Extract Preparation
IO or CP (5 g) was extracted in 50 ml of boiling ethanol
for 1 h, followed by centrifugation at 700 × g for 5 min,
filtration, and concentration using a rotation evaporator. The
obtained extracts were dissolved in 55% ethanol and used in
this study. The final concentration of each extract was 20 mg
of raw material per ml. The final concentration of ethanol was
diluted to 0.5% or less; this concentration has been reported to
show no cytotoxicity (Timm et al., 2013). These samples were
passed through a 0.22-µm membrane filter and used for all
experiments.
Three-Dimensional HPLC Analysis
The ethanol extract (10 µl) of each sample was subjected
to three-dimensional high-performance-liquid chromatography
(HPLC) analysis to detect the chemical constituents. The
HPLC system consisted of a PU-4180 pump, a MD-4015
multiwavelength detector (200–400 nm), and a CO-4060 column
oven (JASCO, Tokyo, Japan). The column was a Mightysil RP-
18GP S (150 × 4.6 mm i.d.; Kanto Chemical Co., Inc., Tokyo,
Japan). The solvents were (A) water/acetonitrile (17:3) and (B)
water/acetonitrile (3:2). A linear gradient of 100% A and 0% B
changing over 45 min to 0% A and 100% B was applied, and
then 0% A and 100% B were continued for 15 min. The flow
rate and the column temperature were 1.0 ml per min and 40◦C,
respectively. Each component was identified by comparing the
peak retention times and wavelengths with those of authentic
compounds.
Cell Culture
LS180 cells were cultured in DMEM+GlutaMAX-1 medium
containing 10% FBS, 100 U/ml penicillin, 100 µg/ml
streptomycin, and 0.1 mM non-essential amino acids at
37◦C in an atmosphere of 95% air/5% CO2. Cells were cultured
to confluence and treated with 100 nM VD3, 10 µM rifampicin,
or ethanol extracts for 48 h. To inhibit PXR activity, 25 µM
ketoconazole was applied 48 h before and during the treatment
described above.
MTT Assay
The MTT assay was performed to assess the cytotoxicity of
ethanol extracts. The MTT assay was performed as previously
described (Lobner, 2000). Briefly, MTT was added to LS180
cells treated with various regents. After incubation for 2 h,
dimethylsulfoxide was added to the cells and the formation of
formazan crystals was measured based on the absorbance change
using a Varioskan Flash 2.4 microplate reader (Thermo Fisher
Scientific, Waltham, MA, USA). Results were normalized to the
absorbance of the blank control.
Immunoblot Analysis of PXR, P-gp, and
CYP3A4 Expression
LS180 cells were lysed in lysis buffer consisting of 20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate, 1 mM sodium orthovanadate,
and 1 µg/ml leupeptin phenylmethanesulfonyl fluoride on
ice and sonicated for 10 s. Cell lysates were centrifuged at
12,000 rpm for 20 min and the supernatant (20 µg protein)
was used for sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis. The lysate was mixed with an equal volume of
sample buffer containing 50 mM Tris-HCl (pH 8.0), 4% SDS,
2% 2-mercaptoethanol, 10% glycerol, and 0.2% bromophenol
blue. After boiling for 5 min, samples were loaded onto
gels and separated, and the proteins were transferred to
nitrocellulose membranes. Following each antibody treatment
(dilution of 1:1000 for all antibodies), protein bands were
visualized using the ECL kit. ImageJ v.1.37 software (National
Institutes of Health, Bethesda, MD, USA) was used to
measure signal intensity, which was normalized to that of
β-actin.
P-gp Activity Assay
P-glycoprotein transport activity was determined to assess
the effect of induction of P-pg protein on P-gp activity
in intestinal epithelial cells. Cells were treated with VD3
or each ethanol extract, and these were washed out after
48 h of incubation. Then, cells were treated with 10 µM
cyclosporine A for 15 min to inhibit P-gp activity. After the
cyclosporine A was washed out, P-gp activity was measured
using the Multi-Drug Resistance Assay kit according to the
manufacturer’s instructions. Phosphate buffer containing 2 µM
calcein-AM was added to the sample, followed by incubation for
30 min. Calcein fluorescence was measured using a microplate
reader.
CYP3A4 Activity Assay
Cytochrome P450 3A4 metabolism was evaluated to assess the
effect of induction of CYP3A4 protein on CYP3A4 activity
in intestinal epithelial cells. Each reagent was added to the
cultured cells and washed out after 48 h of incubation. Then,
10 mM ketoconazole was applied for 15 min to inhibit
CYP3A4 activity. After the ketoconazole was washed out,
CYP3A4 activity was measured using the P450-Glo assay
kit according to the manufacturer’s instructions. Culture
medium containing 3 µM luciferin-IPA, a highly specific
CYP3A4 substrate, was added to the cells for 1 h, followed
by addition of luciferin detection reagent for 30 min.
Luciferin fluorescence was measured using a microplate
reader.
Measurement of Intracellular Drug
Concentration
After treatment with various reagents for 48 h, the reagents
were washed out, and the treated cells were used for
experiments. The treated cells were incubated with 0.1 µM
digoxin or 0.4 µM testosterone for 90 min. To inhibit P-gp
and CYP3A4 activity, cells were pretreated with 10 µM
cyclosporine A or 10 mM ketoconazole for 30 min before
treatment with digoxin or testosterone, respectively. After the
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removal of culture medium and washing out of any residual
reagent, the cells were sonicated. The lysates were centrifuged
at 12,000 rpm for 10 min, and supernatants were used
for the assay. Digoxin and testosterone concentrations were
measured by chemiluminescent immunoassay using Architect
digoxin and testosterone assay kits, respectively. The amount
of protein in each sample was measured by the Bradford
method and results were normalized to the amount of total
protein.
Data Analysis
Each experiment was performed three times, and results are
expressed as the mean ± SD. One-way analysis of variance was
used to compare group means, and differences between groups
were analyzed using the Bonferroni method. All recorded P
values were two-sided, and P < 0.05 was considered statistically
significant.
RESULTS
Three-Dimensional High-Performance
Liquid Chromatography
The components of IO or CP ethanol extracts were analyzed
by three-dimensional high-performance liquid chromatography
(Figures 1A,B). Narirutin and naringin were the main
compounds in IO ethanol extracts, and narirutin and hesperidin
were the main components in CP ethanol extracts. Almost no
other compounds were detected in each extract.
Cytotoxicity of IO and CP Ethanol
Extracts
The MTT assay was used to assess the cytotoxicity of the ethanol
extracts to LS180 cells. The extracts were not toxic up to a
concentration of 20 mg of raw material per ml (Figure 2).
FIGURE 1 | Three-dimensional HPLC analysis of (A) IO and (B) CP ethanol extracts.
FIGURE 2 | Evaluation of IO (A) and CP (B) cytotoxicity. Results represent the mean ± SD of three separate measurements and are expressed relative to a
concentration of 0 mg of raw material per ml; IO, Kijitsu; CP, Chinpi.
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FIGURE 3 | Effect of IO and CP on protein expression of (A) P-gp and (B) CYP3A4. Bar graphs show the average signal strength. Results represent the
mean ± SD of three separate measurements and are expressed relative to the control. ∗P < 0.01. CYP3A4, cytochrome P450 3A4; IO, Kijitsu; P-gp, p-glycoprotein;
CP, Chinpi; VD3, 1α,25-dihydroxyvitamin D3.
FIGURE 4 | IO and CP upregulate PXR protein. Bar graphs show the
average signal strength. Results represent the mean ± SD of three separate
measurements and are expressed relative to the control. ∗P < 0.01. IO,
Kijitsu; PXR, pregnane X receptor; Rif, rifampicin; CP, Chinpi.
Based on these results, we used IO and CP ethanol extracts at a
concentration of 20 mg of raw material per ml in all experiments.
PXR-Induced Upregulation of P-gp and
CYP3A4 in LS180 Cells Treated with
IO or CP
We measured changes in P-gp and CYP3A4 protein expression in
LS180 cells treated with IO or CP ethanol extracts. As previously
reported, P-gp and CYP3A4 were upregulated by VD3 treatment
(Inami et al., 2015); the expression of these proteins was also
increased by approximately 2.0- and 2.5-fold by IO and CP
treatment, respectively, relative to controls (Figures 3A,B). To
clarify the mechanism, the protein level of the PXR, a nuclear
receptor regulating the expression of P-gp and CYP3A4, was
determined (Figure 4). VD3 has been reported to induce P-gp
and CYP3A4 protein expression in a PXR-independent manner
(Schmiedlin-Ren et al., 2001). We found that the PXR protein
level was unaltered by VD3 treatment in LS180 cells. In contrast,
it was increased by treatment with IO or CP ethanol extract, as
well as treatment with rifampicin, a PXR inducer (Jiang et al.,
2009). P-gp and CYP3A4 protein levels were increased by VD3
treatment despite pretreatment with ketoconazole, a PXR activity
inhibitor (Figures 5A,B). In contrast, ketoconazole abrogated the
increases in P-gp and CYP3A4 protein expression induced by
rifampicin, consistent with previous reports (Huang et al., 2007;
Svecova et al., 2008), as well as the increases induced by IO or
CP ethanol extracts. These results indicate that IO and CP induce
P-gp and CYP3A4 expression via upregulation of PXR in LS180
cells.
Pharmacokinetic Changes Induced by IO
and CP
We analyzed the pharmacokinetic effects of P-gp and CYP3A4
upregulation in LS180 cells. The drug extrusion activity of
P-gp was increased by extract treatment (Figure 6A). Moreover,
the intracellular concentration of the P-gp substrate digoxin
decreased in the presence of both IO and CP (Figure 6B),
and this effect was abrogated by treatment with the P-gp
inhibitor cyclosporine A. CP but not IO extract increased the
metabolic activity of CYP3A4 (Figure 7A). The intracellular
concentration of testosterone, a CYP3A4 substrate, was decreased
by CP but not IO treatment (Figure 7B), and this effect was
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FIGURE 5 | Ketoconazole inhibits the upregulation of (A) P-gp and (B) CYP3A4 by IO and CP. Ketoconazole (25 µM) was pretreated 48 h before and during IO
or CP treatment to inhibit PXR activity. Bar graphs show the average signal strength. The results represent the mean ± SD of three separate measurements and are
expressed relative to the control. ∗P < 0.05. CYP3A4, cytochrome P450 3A4; IO, Kijitsu; P-gp, p-glycoprotein; Rif, rifampicin; CP, Chinpi; VD3,
1α,25-dihydroxyvitamin D3.
FIGURE 6 | Effects of IO and CP on (A) P-gp activity and (B) intracellular concentrations of the P-gp substrate digoxin. Cells were pretreated with cyclosporine A
(10 µM) for 15 min to inhibit P-gp activity before addition of DG. Results represent the mean ± SD of three separate measurements and are expressed relative to the
control without cyclosporine A. ∗P < 0.01, ∗∗P < 0.01 vs. control. CsA, cyclosporine A; DG, digoxin; IO, Kijitsu, P-gp, p-glycoprotein; CP, Chinpi; VD3,
1α,25-dihydroxyvitamin D3.
inhibited by short-term treatment with the CYP3A4 inhibitor
ketoconazole.
DISCUSSION
Our study demonstrated that IO and CP ethanol extracts
increased P-gp and CYP3A4 protein levels in LS180 cells,
which was associated with increased PXR expression.
While CP decreased intracellular substrate concentrations
of both P-gp and CYP3A4, IO acted only on the
former.
The expression of P-gp and CYP3A4 is mediated by various
factors; VD3 has been shown to increase P-gp and CYP3A4
levels in a VDR-dependent manner (Schmiedlin-Ren et al., 2001),
whereas rifampicin exerts a similar effect via PXR induction
and activation (Healan-Greenberg et al., 2008; Svecova et al.,
2008). In our study, IO and CP ethanol extracts increased PXR
expression. Moreover, the upregulation of P-gp and CYP3A4 by
IO and CP was inhibited by pretreatment with ketoconazole,
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FIGURE 7 | Effects of IO and CP on (A) CYP3A4 activity and (B) intracellular concentrations of the CYP3A4 substrate testosterone. Cells were pretreated with
ketoconazole (10 mM) for 15 min to inhibit CYP3A4 activity before addition of TS. Results represent the mean ± SD of three separate measurements and are
expressed relative to the control without ketoconazole. ∗P < 0.01, ∗∗P < 0.01 vs. control, ∗∗∗P < 0.05 vs. control. CYP3A4, cytochrome P450 3A4, keto,
ketoconazole; IO, Kijitsu, CP, Chinpi; TS, testosterone; VD3, 1α,25-dihydroxyvitamin D3.
a PXR activity inhibitor. These results indicate that IO and
CP ethanol extract increased P-gp and CYP3A4 expression via
upregulation of PXR. Moreover, P-gp and CYP3A4 induced by
IO and CP showed adequate extrusion or metabolism ability
(Figures 6 and 7). This indicated that these proteins were
expressed at appropriate site and folded adequately. Constitutive
androstane receptor 1 (CAR1) is an important transcription
receptor for inducing P-gp and CYP3A4 expression (Goodwin
et al., 2002). However, a previous study demonstrated that CAR1
transcripts were not expressed in LS 180 cells (Gupta et al.,
2008). These data support our results that induction of P-gp and
CYP3A4 protein by IO and CP in LS180 cells is mediated by
PXR.
Pregnane X receptor is a key protein controlling drug
absorption and metabolism in the intestine via regulation of
P-gp and CYP3A4 activity. Therefore, agents that alter PXR
activity are expected to affect the absorption and metabolism
of concomitantly administered drugs (Qiao et al., 2013). PXR
activity is altered in at least one of the following ways: (i)
activation of PXR function by PXR ligands or (ii) induction
of PXR protein expression (Yang et al., 2011). Most P-gp and
CYP3A4 inducers are PXR ligands and activate PXR function,
and a few directly stimulate PXR protein expression. It has been
reported that hesperetin, which is one of the main flavonoids
in CP, did not affect PXR-dependent transcriptional activity
in a luciferase reporter assay (Satsu et al., 2008). Moreover,
there are no reports showing that narirutin, the main flavonoid
in each extract in the present study, affects PXR-dependent
transcriptional activity. Therefore, in our study, we focused
on the PXR expression change induced by IO and CP. We
speculated that narirutin was a key compound that upregulated
PXR expression, because narirutin was a common compound
in each extract. Alternatively, the flavonoids contained in
each ingredient might cooperate to increase the expression of
PXR. Although the detailed mechanism by which narirutin
induces PXR expression remains unclear, this is the first report
demonstrating upregulation of PXR by components of kampo.
IO and CP ethanol extracts induced P-gp excretion, indicating
that kampo containing IO or CP may alter the absorption
of P-gp substrates in the intestine via upregulation of P-gp
protein. We also showed that CP induced metabolism and
decreased the intracellular concentration of CYP3A4 substrate,
whereas IO did not have this effect despite inducing upregulation
of CYP3A4 protein. These suggested that bioavailability of
the substrates may decrease via the upregulation of P-gp
and CYP3A4 in intestinal epithelial cells when IO or CP
is administered. Our results provide novel evidence for a
mechanism of interaction between kampo including IO and CP
and other drugs via the upregulation of P-gp and CYP3A4.
A previous study revealed that naringin and hesperidin had
inhibitory effects on CYP3A4 (Ho et al., 2001). The effect
of naringin on the inhibition of CYP3A4 might have been
clearly observed because of the difference in the content of
the CYP3A4 inhibitor flavonoid in each extract. Our results
highlight differences in the pharmacokinetic changes induced by
IO and CP.
Flavonoids included in IO and CP have various
pharmacological effects (Tokunaga et al., 2016). Ethanol extracts
of crude drugs include both hydrophilic and hydrophobic
flavonoids. In our study, the water extract of IO and CP increased
P-gp and CYP3A4 protein expression, but this effect was weaker
than that of ethanol extracts (data not shown). A previous study
revealed that narirutin could be extracted from citrus fruits
with the highest yield when using 50–70% ethanol solution;
the amount of narirutin extracted by water was half of that
extracted using 50–70% ethanol solution (Miyake, 2006). The
lower amount of narirutin in the water extract of IO and CP
might be the reason why the water extract of IO and CP had a
weaker effect on the upregulation of P-gp and CYP3A4 protein
expression in the present study.
IO and CP are used as a traditional medicine for treatment of
abdominal symptoms. Daisaiko-to, which contains IO, has anti-
hypercholesterolemic effects (Yoshie et al., 2004); rikkunshi-to,
which contains CP, has been reported to exert orexigenic effects
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by stimulating ghrelin secretion (Hayakawa et al., 2014). Thus,
kampo containing IO and CP has various clinical applications.
However, based on our results, the possibility of pharmacokinetic
changes with concomitant drug use should be considered when
administering kampo containing IO and CP as a treatment.
We examined changes in intracellular drug concentration
using LS180 cells, which are a suitable intestinal epithelial cell
model to analyze interactions between drugs and epithelial cells
(Gupta et al., 2008; Lau et al., 2013), although in vivo studies are
needed to confirm our findings. A previous study demonstrated
that hochuekki-to containing CP increased CYP3A4 expression
in the intestine and decreased the area under the curve for
the CYP3A4 substrate nifedipine (Kinoshita et al., 2011). This
indicated that that induction of P-gp and CYP3A4 protein via
upregulation of PXR in intestinal epithelial cells may occur
in vivo. However, it was recently reported that daisaiko-to
containing IO increased the area under the curve for nifedipine
in vivo (He et al., 2014); although the underlying mechanism
is unclear, this finding suggests that the activity and expression
of P-gp and CYP3A4 may differ according kampo formulations.
Therefore, a more detailed analysis of different types of kampo is
needed to broaden its clinical applicability.
CONCLUSION
Our study demonstrated that ethanol extracts of IO and
CP induced P-gp and CYP3A4 expression via upregulation
of PXR and decreased intracellular substrate concentrations,
thereby potentially perturbing drug absorption and metabolism.
Although further analyses are needed to confirm our results,
these findings provide information that can inform the safe use
of kampo.
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